Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Drug Delivery Systems: Delayed-Release Systems01:11

Oral Drug Delivery Systems: Delayed-Release Systems

24
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
24
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions01:29

Hypersensitivity Reactions: Delayed Hypersensitivity Reactions

18
Delayed-Type Hypersensitivity (DTH), or Type IV hypersensitivity, is a cell-mediated immune response. It occurs when T cells, rather than antibodies, mediate a reaction to specific antigens. It is characterized by a delayed onset (1-2 days) and involves the recruitment of macrophages to the inflammation site.The initiation of a DTH response begins with the sensitization of T cells. During this phase, which lasts at least 1-2 weeks, antigen-specific T cells are activated, clonally expanded, and...
18
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

802
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
802
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

932
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
932
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

715
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
715
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

652
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
652

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First-line surgery in prolactinomas: lessons from a long-term follow-up study in a tertiary referral center.

Journal of endocrinological investigation·2021
Same author

Lhermitte-Duclos disease with atypical vascularization--case report and review of the literature.

Clinical neuropathology·2009
Same author

Cerebellar haemangioblastoma and invasive macroprolactinoma: case report.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia·2008
Same author

Contribution of the apparent diffusion coefficient in perilesional edema for the assessment of brain tumors.

Journal of neuroradiology = Journal de neuroradiologie·2008
Same author

Morbidity in 201 patients with small sized meningioma treated by microsurgery.

Acta neurochirurgica·2006
Same author

Cerebral revascularization model in a swine.

Acta neurochirurgica. Supplement·2005

Related Experiment Video

Updated: Feb 16, 2026

Longitudinal Intravital Imaging of Brain Tumor Cell Behavior in Response to an Invasive Surgical Biopsy
09:17

Longitudinal Intravital Imaging of Brain Tumor Cell Behavior in Response to an Invasive Surgical Biopsy

Published on: May 3, 2019

7.9K

Delayed response to brain tumor chemotherapy.

R W Seiler

    Surgical Neurology
    |February 1, 1979
    PubMed
    Summary
    This summary is machine-generated.

    Recurrent malignant gliomas may show delayed improvement after initial chemotherapy worsening. This suggests slow clearance of dead tumor cells, necessitating prolonged observation for accurate treatment response assessment.

    More Related Videos

    Transplantation of Zebrafish Pediatric Brain Tumors into Immune-competent Hosts for Long-term Study of Tumor Cell Behavior and Drug Response
    09:43

    Transplantation of Zebrafish Pediatric Brain Tumors into Immune-competent Hosts for Long-term Study of Tumor Cell Behavior and Drug Response

    Published on: May 17, 2017

    12.1K
    Establishing Intracranial Brain Tumor Xenografts With Subsequent Analysis of Tumor Growth and Response to Therapy using Bioluminescence Imaging
    11:09

    Establishing Intracranial Brain Tumor Xenografts With Subsequent Analysis of Tumor Growth and Response to Therapy using Bioluminescence Imaging

    Published on: July 13, 2010

    40.5K

    Related Experiment Videos

    Last Updated: Feb 16, 2026

    Longitudinal Intravital Imaging of Brain Tumor Cell Behavior in Response to an Invasive Surgical Biopsy
    09:17

    Longitudinal Intravital Imaging of Brain Tumor Cell Behavior in Response to an Invasive Surgical Biopsy

    Published on: May 3, 2019

    7.9K
    Transplantation of Zebrafish Pediatric Brain Tumors into Immune-competent Hosts for Long-term Study of Tumor Cell Behavior and Drug Response
    09:43

    Transplantation of Zebrafish Pediatric Brain Tumors into Immune-competent Hosts for Long-term Study of Tumor Cell Behavior and Drug Response

    Published on: May 17, 2017

    12.1K
    Establishing Intracranial Brain Tumor Xenografts With Subsequent Analysis of Tumor Growth and Response to Therapy using Bioluminescence Imaging
    11:09

    Establishing Intracranial Brain Tumor Xenografts With Subsequent Analysis of Tumor Growth and Response to Therapy using Bioluminescence Imaging

    Published on: July 13, 2010

    40.5K

    Area of Science:

    • Neuro-oncology
    • Clinical Neurology
    • Medical Imaging

    Background:

    • Malignant gliomas are aggressive brain tumors with poor prognoses.
    • Recurrent gliomas often present challenges in treatment and response evaluation.
    • Chemotherapy is a standard treatment modality for malignant gliomas.

    Observation:

    • Five cases of recurrent malignant gliomas exhibited initial clinical and scintigraphic deterioration during chemotherapy.
    • A subsequent, long-lasting improvement in clinical status and brain scans was observed.
    • This delayed response pattern was unexpected following initial negative progression.

    Findings:

    • The study suggests that initial deterioration may be due to swollen dead tumor cells and secondary inflammation.
    • Slow clearance of dead tumor cells from the brain could explain the delayed positive response.
    • This phenomenon has been supported by experimental observations.

    Implications:

    • Accurate assessment of chemotherapy response in malignant gliomas requires extended serial observation periods.
    • The findings challenge the immediate interpretation of initial clinical deterioration as treatment failure.
    • Understanding this delayed response mechanism may inform future treatment strategies for recurrent gliomas.